The endocannabinoid that is also a vanilloid. NADA couples anandamide's fatty tail to dopamine's head — activating cannabinoid receptors and the capsaicin TRPV1 channel at once.
Cannabinoid and vanilloid activation — pain biology
Synthesis & Release
NADA is an amide of arachidonic acid with dopamine — a molecular chimera of two signaling systems, dopamine and endocannabinoid chemistry fused in one molecule. Found in striatum and sensory neurons at nanomolar levels, it rises with cellular activity and acts as one of the endovanilloids — the body's own capsaicin-like ligands, sensing heat and inflammation at the peripheral terminal. Its dual activation profile — potent TRPV1 opening plus CB1 agonism — placed it at the pain-inflammation interface, where desensitization therapies also act.
Receptor Actions
TRPV1: NADA is among the most potent endogenous activators — the receptor capsaicin and heat also open.
CB1: agonist activity adds the cannabinoid arm — retrograde modulation like its cousins.
The pairing links nociception and endocannabinoid tone in one molecule.
Physiological Role
Pain modulation at dorsal-root synapses — where vanilloid and cannabinoid systems meet.
Striatal signaling adds a dopamine-adjacent lipid signal to basal ganglia chemistry — see dopamine.